ArticleBMC microbiology2026
Probiotic potential of Companilactobacillus alimentarius Y4 in alleviating ciprofloxacin-resistant Salmonella-induced intestinal inflammation through microbiota-metabolite modulation.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The emergence of ciprofloxacin-resistant Salmonella poses a significant challenge to antimicrobial therapy. Probiotics that inhibit ciprofloxacin-resistant Salmonella offer a safer alternative with fewer side effects than conventional antibiotics. In this study, a strain of Companilactobacillus alimentarius Y4, isolated from kimchi, exhibited strong antibacterial activity against Salmonella C1, Escherichia coli, and other intestinal pathogens. Biological characterization showed that C. alimentarius Y4 maintained a relative growth rate of 80% at pH 3.0 and 87.13% in the presence of 0.3% bile salts. It retained over 98.8% antibacterial activity even after exposure to pepsin, trypsin, protease K, and catalase. Additionally, C. alimentarius Y4 downregulated the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), while upregulating the anti-inflammatory cytokine IL-10, which may contribute to alleviating intestinal injury induced by ciprofloxacin-resistant Salmonella C1. Gut microbiota analysis revealed that C. alimentarius Y4 colonized the intestine and increased the abundance of beneficial gut microbes, including Lachnospiraceae bacterium COE1 and Muribaculaceae bacterium CAG-485. Metabolomic profiling further indicated that C. alimentarius Y4 upregulated metabolites such as L-leucine, L-lysine, and tryptophan, contributing to the restoration of intestinal metabolic balance. Collectively, C. alimentarius Y4 may mitigate intestinal inflammation by regulating cytokine expression, repairing mucosal damage, rebalancing gut microbiota composition, and restoring metabolic homeostasis. These findings indicate that C. alimentarius Y4 may contribute to alleviating intestinal inflammatory damage caused by multidrug-resistant Salmonella infection, suggesting its potential as a promising probiotic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.